10x Research: The $56,000/$57,000 area is expected to become a significant resistance level for Bitcoin
10x Research stated in its latest report that Monday's Bitcoin plunge is a key reference point in the market's recent history. Traders focus on the technical aspects of price changes, and even the most optimistic cryptocurrency traders must admit that declines are getting larger: The low in May was $56,500, July was $53,500, and August was $49,100. Although Bitcoin is currently trying to recover, after breaking through recent support levels, strong resistance from a clear downward trend may be more challenging. Our bearish outlook stems from monthly technical indicators which have reached historical reversal levels seen in past bull markets (such as January 2018 and April 2021) by May 2024.
We can only confirm this several months later. However, it has cyclically affected our expectations for price drops in April, June and August 2024. From a technical perspective,the area around $56k-$57k is expected to become significant resistance for Bitcoin; exceeding this level would be a positive signal. However,due to the general downside risk shown by incomplete technical indicators,it's crucial to set firm stop losses for long positions ($54k).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
This Isn’t a Crypto Crash. Fed Hike Bets Are Hitting Everything

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar
Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion
Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.
